{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:04:54Z","timestamp":1758636294742,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1053\/j.seminhematol.2004.09.002","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S7","title":["New treatment strategies for multiple myeloma"],"prefix":"10.1053","volume":"41","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2003","series-title":"Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide (T) (DVd-T) in newly diagnosed (Nmm) and relapsed\/refractory (Rmm) multiple myeloma patients.","author":"Agrawal","key":"10.1053\/j.seminhematol.2004.09.002_bib1"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib5","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2003-01-0073","article-title":"Transplantation for multiple myeloma","volume":"102","author":"Blade","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1992.tb06466.x","article-title":"Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma","volume":"82","author":"Browman","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR)","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin, and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib10","first-page":"276a","article-title":"Slow incremental dosing of thalidomide improves tolerance and duration of therapy in myeloma patients","volume":"21","author":"Farray","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib11","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"10.1053\/j.seminhematol.2004.09.002_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.thj.6200150","article-title":"The combination of thalidomide, cyclophosphamide, and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed\/refractory multiple myeloma","volume":"3","author":"Garcia-Sanz","year":"2002","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib16","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib17","first-page":"403a","article-title":"Doxil (D), vincristine (V), Decadron (d) and thalidomide (T) (DVd-T) for relapsed\/refractory multiple myeloma (RMM)","volume":"100","author":"Hussein","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001622-200201000-00006","article-title":"Multiple myeloma","volume":"14","author":"Hussein","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib19","unstructured":"Hussein MA, Rifkin R, Gregory SA, et al: DVd versus VAd in the treatment of patients with newly diagnosed multiple myeloma (n-MM): An update from a randomized multicenter trial. Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib22","first-page":"8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib23","unstructured":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2004. Available at: http:\/\/www.nccn.org\/physician_gls\/f_guidelines.html. Accessed April 5, 2004"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","article-title":"Thalidomide\u2014A revival story","volume":"341","author":"Raje","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib26","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Blood E, Vesole DH, et al: A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004","DOI":"10.1200\/jco.2004.22.90140.6508"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib28","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bjc.6690070","article-title":"Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma","volume":"79","author":"Ribatti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib30","unstructured":"Rifkin RM, Hussein MA, Gregory SA, et al: Final results: Multicenter trial of DVd vs VAd in newly diagnosed multiple myeloma. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil)","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V85.7.1903.bloodjournal8571903","article-title":"CD40 ligand triggered interleukin-6 secretion in multiple myeloma","volume":"85","author":"Urashima","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib35","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V87.5.1928.1928","article-title":"Transforming growth factor-beta1","volume":"87","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil)","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2004.09.002_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00002512-200219020-00002","article-title":"Thalidomide in cancer treatment","volume":"19","author":"Zhou","year":"2002","journal-title":"Drugs Aging"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:15:30Z","timestamp":1758521730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196304001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":39,"alternative-id":["S0037196304001891"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.09.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment strategies for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}